BiotechTube

G-Pen + Lilly Glucagon

Phase 3Completed
0 watching 0 views this week📈 Rising
72
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Insulin Hypoglycemia

Conditions

Insulin Hypoglycemia, Type 1 Diabetes Mellitus, Severe Hypoglycemia

Trial Timeline

Jan 23, 2018 → May 3, 2018

NCT ID
NCT03439072

About G-Pen + Lilly Glucagon

G-Pen + Lilly Glucagon is a phase 3 stage product being developed by Xeris Pharmaceuticals for Insulin Hypoglycemia. The current trial status is completed. This product is registered under clinical trial identifier NCT03439072. Target conditions include Insulin Hypoglycemia, Type 1 Diabetes Mellitus, Severe Hypoglycemia.

Hype Score Breakdown

Clinical
27
Activity
18
Company
5
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT03439072Phase 3Completed

Competing Products

20 competing products in Insulin Hypoglycemia

See all competitors
ProductCompanyStageHype Score
naveglitazarEli LillyPhase 2
52
AC2993 + AC2993 + Placebo + PlaceboAstraZenecaPhase 3
77
Dapagliflozin 10 mg + Placebo tabletAstraZenecaPhase 3
77
Placebo 0.01 mL + Placebo 0.02 mL + Placebo 0.03 mL + Placebo 0.04 mL + AC2993 2.5 mcg + AC2993 5.0 mcg + AC2993 7.5 mcg + AC2993 10.0 mcgAstraZenecaPhase 2
52
Atropine + Physostigmine + Placebo SodiumAstraZenecaPhase 1
33
SaxagliptinAstraZenecaApproved
85
AC2993 + AC2993 + Placebo + PlaceboAstraZenecaPhase 3
77
Pramlintide acetateAstraZenecaPhase 2
52
sitagliptin + Comparator: glimepiride + open-label metforminMerckPhase 3
77
sitagliptinMerckApproved
85
sitagliptin phosphateMerckPhase 3
77
MK-1006 + PlaceboMerckPhase 1
33
Comparator: Placebo + Sitagliptin + VogliboseMerckPhase 3
77
sitagliptin phosphate + Comparator: metformin + Comparator: metformin + Comparator: Antidiabetic Standard of CareMerckPhase 3
77
Placebo + MK-0941MerckPhase 1
33
Placebo + PrednisoloneMerckPre-clinical
23
Comparator: exenatide + Comparator: exenatide + Comparator: PlaceboMerckPhase 1
33
simvastatin/ezetimibe + atorvastatin 20mgMerckApproved
85
sitagliptin phosphate + Comparator: Placebo + Comparator: SitagliptinMerckPhase 2
52
sitagliptin phosphateMerckPhase 1
33

Other Products from Xeris Pharmaceuticals

G-Pen (glucagon injection) + Lilly Glucagon (glucagon injection [rDNA origin])Phase 3
72
G-Pen + Novo GlucagonPhase 3
72
GlucagonPhase 3
72
Glucagon RTUPhase 2
47
PRAM9 + Regular Insulin + Pramlintide + Regular InsulinPhase 2
47